Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'

May 14, 2026 7:29 AM

Stifel analyst Paul Matteis reiterated a Buy rating and $214.00 price target on Biogen (NASDAQ: BIIB)The analyst comments "Biogen announced ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

StreetInsider

Log in to your account:

Stifel on Biogen (BIIB): 'We want to be a little cautious here until we see the full data'

Categories

Next Articles